AIM Conference Set for December 1
This Thursday, December 1, Aging in Motion will host its second annual meeting with leaders from the U.S. Food and Drug Administration (FDA) and leading scientists, industry representatives, and advocates to highlight the latest developments in clinical research and treatment of sarcopenia. It will be held at the Bethesda North Marriott Hotel & Conference Center in Bethesda, Md. The theme is “Advancing Theraputic Development for Sarcopenia: Efforts to Improve Clinical Detection and EndPoint Measures.”
Below is more information on the meeting. To register, please go here.
In March of 2014, the Aging In Motion (AIM) Coalition held its first meeting with representatives from the U.S. Food and Drug Administration and other thought leaders to explore how Patient-Reported Outcome (PRO) measures could play a role in clinical trials for sarcopenia treatments. During the meeting, presentations also highlighted progress toward defining sarcopenia as a disease and efforts to advance performance-based outcome measures in this space.
Despite recent recognition of sarcopenia as a disease by the Centers for Disease Control and Prevention and acknowledgement from the FDA that sarcopenia is a disease worthy of further exploration through their Patient-Focused Drug Development Initiative, there are currently no drugs approved for the treatment of sarcopenia. The primary goal for this meeting is to advance therapeutic development for sarcopenia by providing an update for stakeholders on efforts to improve the clinical detection of sarcopenia and bridging knowledge from initiatives underway in the public and private sectors to identify appropriate measures for use as endpoints in clinical trials.